Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Immunization induces activation of bone marrow eosinophils required for plasma cell survival.

Chu VT, Berek C.

Eur J Immunol. 2012 Jan;42(1):130-7. doi: 10.1002/eji.201141953. Epub 2011 Nov 28.

2.

Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL.

Benson MJ, Dillon SR, Castigli E, Geha RS, Xu S, Lam KP, Noelle RJ.

J Immunol. 2008 Mar 15;180(6):3655-9.

3.

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells.

Belnoue E, Pihlgren M, McGaha TL, Tougne C, Rochat AF, Bossen C, Schneider P, Huard B, Lambert PH, Siegrist CA.

Blood. 2008 Mar 1;111(5):2755-64. doi: 10.1182/blood-2007-09-110858. Epub 2008 Jan 7.

4.

Eosinophils are required for the maintenance of plasma cells in the bone marrow.

Chu VT, Fröhlich A, Steinhauser G, Scheel T, Roch T, Fillatreau S, Lee JJ, Löhning M, Berek C.

Nat Immunol. 2011 Feb;12(2):151-9. doi: 10.1038/ni.1981. Epub 2011 Jan 9.

PMID:
21217761
5.

Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow.

Matthes T, Dunand-Sauthier I, Santiago-Raber ML, Krause KH, Donze O, Passweg J, McKee T, Huard B.

Blood. 2011 Aug 18;118(7):1838-44. doi: 10.1182/blood-2011-01-332940. Epub 2011 Jun 3.

6.

Novel function of TNF cytokines in regulating bone marrow B cell survival.

Zhang M, Ko KH, Lam QL, Lo CK, Xu DJ, Shen L, Zheng B, Srivastava G, Lu L.

Cell Mol Immunol. 2004 Dec;1(6):447-53.

7.

Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals.

Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M, Muehlinghaus G, Szyska M, Radbruch A, Manz RA.

J Immunol. 2003 Aug 15;171(4):1684-90.

8.

Basophils support the survival of plasma cells in mice.

Rodriguez Gomez M, Talke Y, Goebel N, Hermann F, Reich B, Mack M.

J Immunol. 2010 Dec 15;185(12):7180-5. doi: 10.4049/jimmunol.1002319. Epub 2010 Nov 10.

9.

Static and dynamic components synergize to form a stable survival niche for bone marrow plasma cells.

Zehentmeier S, Roth K, Cseresnyes Z, Sercan Ö, Horn K, Niesner RA, Chang HD, Radbruch A, Hauser AE.

Eur J Immunol. 2014 Aug;44(8):2306-17. doi: 10.1002/eji.201344313. Epub 2014 May 30.

10.

The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity.

Minges Wols HA, Underhill GH, Kansas GS, Witte PL.

J Immunol. 2002 Oct 15;169(8):4213-21.

12.

Survival of long-lived plasma cells is independent of antigen.

Manz RA, Löhning M, Cassese G, Thiel A, Radbruch A.

Int Immunol. 1998 Nov;10(11):1703-11.

PMID:
9846699
13.

Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor.

Mayer ML, Phillips CM, Stadnyk AW, Halperin SA, Lee SF.

Mol Immunol. 2009 May;46(8-9):1883-91. doi: 10.1016/j.molimm.2009.02.008. Epub 2009 Mar 10.

PMID:
19278729
14.

In vitro and in vivo activation induces BAFF and APRIL expression in B cells.

Chu VT, Enghard P, Riemekasten G, Berek C.

J Immunol. 2007 Nov 1;179(9):5947-57.

15.

Interleukin 5 immunotherapy depletes alloreactive plasma cells.

Redfield RR, Rodriguez E, Luo Y, Rostami S, Parsons RF, Noorchashm H, Abt PL, Naji A.

J Surg Res. 2014 Mar;187(1):310-5. doi: 10.1016/j.jss.2013.10.028. Epub 2013 Oct 19.

PMID:
24267616
16.

Pentoxifylline functions as an adjuvant in vivo to enhance T cell immune responses by inhibiting activation-induced death.

Suresh R, Vig M, Bhatia S, Goodspeed EP, John B, Kandpal U, Srivastava S, George A, Sen R, Bal V, Durdik JM, Rath S.

J Immunol. 2002 Oct 15;169(8):4262-72.

18.

4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Cannons JL, Lau P, Ghumman B, DeBenedette MA, Yagita H, Okumura K, Watts TH.

J Immunol. 2001 Aug 1;167(3):1313-24.

19.

TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo.

Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y.

J Exp Med. 2000 Feb 7;191(3):495-502.

20.

PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA.

Shen E, Li L, Li L, Feng L, Lu L, Yao Z, Lin H, Wu C.

Cell Mol Immunol. 2007 Apr;4(2):113-20.

Supplemental Content

Support Center